详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Eriodictyol Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity.

12| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Biochemistry and Molecular Biology, Key Laboratory of Biological Molecular Medicine Research of Guangxi Higher Education, Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi, China [2]School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, Western Australia, Australia [3]Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China [4]Department of Orthopaedic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China [5]Institute of Functional Biomolecules, Medical School, Nanjing University, Nanjing, Jiangsu, China [6]Research Center for Drug Discovery (RCDD), School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, China [7]Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China [8]The Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia [9]Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, China

出处：

DOI：

ISSN：

摘要：

Receptor activator of nuclear factor kappa-B ligand (RANKL) induces differentiation and function of osteoclasts through triggering multiple signaling cascades, including NF-κB, MAPK, and Ca(2+) -dependent signals, which induce and activate critical transcription factor NFATc1. Targeting these signaling cascades may serve as an effective therapy against osteoclast-related diseases. Here, by screening a panel of natural plant extracts with known anti-inflammatory, anti-tumor, or anti-oxidant properties for possible anti-osteoclastogenic activities we identified Eriodictyol. This flavanone potently suppressed RANKL-induced osteoclastogenesis and bone resorption in a dose-dependent manner without detectable cytotoxicity, suppressing RANKL-induced NF-κB, MAPK, and Ca(2+) signaling pathways. Eriodictyol also strongly inhibited RANKL-induction of c-Fos levels (a critical component of AP-1 transcription factor required by osteoclasts) and subsequent activation of NFATc1, concomitant with reduced expression of osteoclast specific genes including cathepsin K (Ctsk), V-ATPase-d2 subunit, and tartrate resistant acid phosphatase (TRAcP/Acp5). Taken together, these data provide evidence that Eriodictyol could be useful for the prevention and treatment of osteolytic disorders associated with abnormally increased osteoclast formation and function. J. Cell. Physiol. 231: 1983-1993, 2016. © 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 2 区生物

小类 | 2 区生理学 3 区细胞生物学

最新[2025]版：

大类 | 3 区生物学

小类 | 3 区细胞生物学 3 区生理学

JCR分区：

出版当年[2014]版：

Q1 PHYSIOLOGY Q2 CELL BIOLOGY

最新[2023]版：

Q1 PHYSIOLOGY Q2 CELL BIOLOGY

影响因子： 4.5 最新[2023版] 5.3 最新五年平均 3.839 出版当年[2014版] 3.751 出版当年五年平均 3.874 出版前一年[2013版] 4.155 出版后一年[2015版]

第一作者：

第一作者机构： [1]Department of Biochemistry and Molecular Biology, Key Laboratory of Biological Molecular Medicine Research of Guangxi Higher Education, Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi, China [2]School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, Western Australia, Australia [3]Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Biochemistry and Molecular Biology, Key Laboratory of Biological Molecular Medicine Research of Guangxi Higher Education, Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi, China [2]School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, Western Australia, Australia [9]Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, China [*1]Department of Biochemistry and Molecular Biology, Key Laboratory of Biological Molecular Medicine Research of Guangxi Higher Education, Medical Scientific Research Center, Guangxi Medical University, Guangxi, China. [*2]School of Pathology and Laboratory Medicine, The University of Western Australia, Perth, Western Australia, Australia.

推荐引用方式(GB/T 7714)：

APA：

MLA：